An N 6 -methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells

• Published in: Biochemical pharmacology Vol. 160; p. 134
• Main Authors: Uddin, Mohammad B, Roy, Kartik R, Hosain, Salman B, Khiste, Sachin K, Hill, Ronald A, Jois, Seetharama D, Zhao, Yunfeng, Tackett, Alan J, Liu, Yong-Yu
• Format: Journal Article
• Language: English
• Published: England 01.02.2019
• Subjects: Adenosine - analogs & derivatives; Adenosine - genetics; beta Catenin - metabolism; Cell Line, Tumor; Codon; Colonic Neoplasms - drug therapy; Colonic Neoplasms - genetics; Drug Resistance, Neoplasm - genetics; Gene Expression Regulation, Neoplastic; Humans; Methyltransferases - genetics; Methyltransferases - metabolism; Mutation, Missense; Oxaliplatin - pharmacology; RNA, Messenger - genetics; Trihexosylceramides - metabolism; Trihexosylceramides - pharmacology; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; N-methyladenosine; Missense mutation; Drug resistance; Glucosylceramide synthase; Tumor suppressor p53; RNA methylation
• ISSN: 1873-2968
• DOI: 10.1016/j.bcp.2018.12.014

Mutant p53 proteins that promote cancer cell invasive growth, metastasis and drug resistance emerge as therapeutic targets. Previously, we reported that suppression of ceramide glycosylation restored wild-type p53 protein and tumor suppressing function in cancer cells heterozygously carrying p53 R273H, a hot-spot missense mutation; however, the mechanisms underlying the control of mutant protein expression remain elusive. Herein, we report that an N -methyladenosine (m A) at the point-mutated codon 273 (G > A) of p53 pre-mRNA determines the mutant protein expression. Methylation of the transited adenosine was catalyzed by methyltransferase like 3 (METTL3), and this m A-RNA promoted a preferential pre-mRNA splicing; consequently, the produced p53 R273H mutant protein resulted in acquired multidrug resistance in colon cancer cells. Furthermore, glycosphingolipids (particularly globotriaosylceramide) generated from serial ceramide glycosylation were seen to activate cSrc and β-catenin signaling so as to upregulate METTL3 expression, in turn promoting expression of p53 R273H mutant protein, with consequent drug resistance. Conversely, either silencing METTL3 expression by using small interfering RNA (siRNA) or inhibiting RNA methylation with neplanocin A suppressed m A formation in p53 pre-mRNA, and substantially increased the level of phosphorylated p53 protein (Ser15) and its function in cells heterozygously carrying the R273H mutation, thereby re-sensitizing these cells to anticancer drugs. Concordantly, suppression of ceramide glycosylation repressed METTL3 expression and m A formation in p53 pre-mRNA, thus sensitizing cells carrying R273H to anticancer drugs. This study uncovers a novel function of pre-mRNA m A as a determinant of mutant protein expression in cancer cells heterozygously carrying the TP53 R273H mutation. Suppressing both RNA methylation and ceramide glycosylation might constitute an efficacious and specific approach for targeting TP53 missense mutations coding for a G > A transition, thereby improving cancer treatments.